Video

Dr. Wang on the Benefit of BTK Inhibitors in MCL

Michael Wang, MD, discusses the benefit of BTK inhibitors in mantle cell lymphoma.

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the benefit of BTK inhibitors in mantle cell lymphoma (MCL).

MCL is one of the most difficult-to-treat lymphomas. As a rare subtype of lymphoma, MCL can be difficult to treat outside of a specialized center, explains Wang. Furthermore, current therapeutic options are not curative, so the prognosis is poor.

However, this is starting to change as the field moves from the use of chemotherapy to chemotherapy-free agents, such as ibrutinib (Imbruvica) and acalabrutinib (Tecentriq), says Wang. Both BTK inhibitors are oral agents that can induce better responses than several chemotherapies combined, he adds. Moreover, patients do not lose their hair as a result of these inhibitors, they don't need a central line, and their blood count levels don't drop. Additionally, the infection rate is much better with these agents, concludes Wang.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity